Phase Ib Trial of CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions Delivered With the Surefire Infusion System (SIS) for CEA-Expressing Liver Metastases or Pancreas Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2018
At a glance
- Drugs CAR-T CEA therapy (Primary)
- Indications Adenocarcinoma; Liver metastases; Pancreatic cancer
- Focus Adverse reactions
- Acronyms HITM-SURE
- 06 Nov 2018 Results presented in a Sorrento Therapeutics media release.
- 06 Nov 2018 According to a Sorrento Therapeutics media release, preliminary data from the study will be presented in a poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2018.
- 14 Jun 2018 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History